You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

The top executives of a company accused of abandoning junked wind-turbine blades across Iowa say they shouldn’t be held ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Eli Lilly's LLY short percent of float has risen 5.88% since its last report. The company recently reported that it has 6.10 million shares sold short, which is 0.72% of all regular shares that are ...

Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $757.6 which represents a slight increase of $10.86 or 1.45% from the prior close of $746.74. The stock opened at $747.5 and touched ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...